Chronic Kidney Disease Market to Witness Slight Decline by 2017
As a result of the loss of patent for major brands in the late-stage chronic kidney disease (CKD) market, and the changing reimbursement environment across the six major markets (6MM), the CKD sales revenue will decrease at a negative Compound Annual Growth Rate (CAGR) of 2.5% between 2012 and 2017, forecasts research and consulting firm GlobalData.
According to the company’s latest report*, the late-stage CKD market in the 6MM (US, France, Germany, Italy, Spain, and UK) will decline from $1.88 billion in 2012 to $1.66 billion by 2017. GlobalData expects that the majority of sales will still come from the US (76%), with marginal increase in the 5EU’s share (24%) during the forecast period.
Savade Solanki, PhD, GlobalData’s Senior Analyst covering Oncology and Hematology, says: “Patent expiries of the major brands Renagel, Renvela, and Zemplar will be a severe barrier for growth for the late-stage CKD market. Additionally, the healthcare reimbursement policy is changing in the US and Europe, which will have a negative impact on the stage 5 hemodialysis treatment market.
“In particular, the 2011 inclusion of intravenous (IV) drugs in the Medicare dialysis reimbursement bundle, and the expected 2016 inclusion of oral treatments, will be a major hurdle to the growth of premium-priced branded agents.”
Furthermore, despite the variety of drugs available for the treatment of hyperphosphatemia and secondary hyperparathyroidism in late-stage CKD patients, GlobalData identifies high unmet needs for treatments with better efficacy in tackling these comorbidities.
“Patients treated with Renvela, the current gold-standard phosphate binder, are taking eight tablets per day on average. As a result of this large pill burden, there is poor patient compliance and adherence not only to phosphate binder treatment, but also oral treatments that are concomitantly given to treat other co-existing comorbidities,” Solanki says.
Other unmet needs, according to GlobalData, include the necessity of well-tolerated and IV-administered calcimimetics, and the earlier diagnosis and treatment of comorbidities. Lower cost of therapy and better clinical guidelines have also been identified as areas for improvement.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance